NASDAQ: ATYR
Atyr Pharma Inc Stock Ownership - Who owns Atyr Pharma?

Insider buying vs selling

Have Atyr Pharma Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Paul SchimmelDirector2025-10-09317,999$0.94
$299.24kBuy
Paul SchimmelDirector2025-10-08682,001$0.90
$612.44kBuy
Jane A. GrossDirector2025-03-173,750$4.00
$15.00kBuy
Jill Marie BroadfootChief Financial Officer2025-02-041,254$3.78
$4.74kSell
Nancy DenyesGeneral Counsel2025-02-04899$3.78
$3.40kSell

1 of 1

ATYR insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ATYR insiders and whales buy or sell their stock.

ATYR Shareholders

What type of owners hold Atyr Pharma Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Fmr LLC15.00%14,697,995$11.99MInstitution
Federated Hermes Inc10.76%10,544,437$8.60MInstitution
Blackrock Inc6.61%6,473,884$5.28MInstitution
Vanguard Group Inc5.75%5,630,935$4.59MInstitution
Ubs Group Ag4.60%4,505,955$3.68MInstitution
State Street Corp4.28%4,196,166$3.42MInstitution
Geode Capital Management LLC2.22%2,178,203$1.78MInstitution
Millennium Management LLC1.93%1,890,921$1.54MInstitution
Srinivas Akkaraju1.90%1,866,126$1.52MInsider
Sofinnova Venture Partners IX LP1.90%1,866,126$1.52MInsider

1 of 3

ATYR vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ATYR63.19%15.70%Net BuyingNet Buying
PPBT0.01%0.00%
KRRO25.74%74.26%
TIL5.64%94.36%Net Buying
CRVO2.96%97.04%Net BuyingNet Buying

Atyr Pharma Stock Ownership FAQ

Who owns Atyr Pharma?

Atyr Pharma (NASDAQ: ATYR) is owned by 63.19% institutional shareholders, 15.70% Atyr Pharma insiders, and 21.11% retail investors. Srinivas Akkaraju is the largest individual Atyr Pharma shareholder, owning 1.87M shares representing 1.90% of the company. Srinivas Akkaraju's Atyr Pharma shares are currently valued at $1.43M.

If you're new to stock investing, here's how to buy Atyr Pharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.